Round Hill Asset Management Grows Position in Pfizer Inc. (NYSE:PFE)

Round Hill Asset Management increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 8.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 152,162 shares of the biopharmaceutical company's stock after acquiring an additional 11,514 shares during the quarter. Pfizer comprises about 2.8% of Round Hill Asset Management's investment portfolio, making the stock its 10th largest position. Round Hill Asset Management's holdings in Pfizer were worth $4,037,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the company. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the 4th quarter worth $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer during the fourth quarter worth $28,000. Noble Wealth Management PBC acquired a new position in Pfizer in the fourth quarter valued at about $31,000. Finally, Curio Wealth LLC bought a new position in Pfizer during the fourth quarter worth about $32,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on PFE shares. UBS Group reduced their price objective on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a research note on Tuesday. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Pfizer has a consensus rating of "Moderate Buy" and a consensus target price of $31.07.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.06% of the company's stock.

Pfizer Stock Down 4.7 %

Pfizer stock traded down $1.06 during mid-day trading on Thursday, reaching $21.43. The company's stock had a trading volume of 37,725,815 shares, compared to its average volume of 40,037,516. The business's 50 day simple moving average is $25.42 and its 200 day simple moving average is $26.51. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a market capitalization of $121.53 billion, a price-to-earnings ratio of 15.24, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.